WHO Disease Outbreak News

Since the previous Disease Outbreak News was published on 11 September 2026, an additional 1133 confirmed cases, including 532 confirmed deaths, have been reported in the Democratic Republic of the Congo. The seven-day moving average shows a resurgence in early September followed by a decline over the most recent reporting days. However, the aggregate national trend conceals substantial variation in transmission intensity across affected provinces and health zones. As of 23 September, the Democratic Republic of the Congo has reported a total of 7890 confirmed cases, including 3799 deaths (CFR 48.1%). A total of 1966 patients have recovered to date. Confirmed cases have been reported from 63 health zones across seven provinces, with 48 health zones from six provinces reporting at least one case in the last 21 days. Ituri remains the most affected province, with 28 of its 36 health zones reporting cases, followed by North Kivu (16/34), Tshopo (7/23), Haut-Uélé (7/13), Bas-Uélé (3/11), South Kivu (1/34), and Sud Ubangi (1/16). No new cases have been reported from South Kivu province since 29 May 2026. Dungu Health Zone in Haut-Uélé province and Bulu in Sud Ubangi are the most recently affected areas. As of 23 September, 70 new confirmed cases had been reported in the preceding 24 hours from 26 health zones located in Ituri, North Kivu, Haut-Uélé, Bas Uélé and Tshopo provinces. Figure 1. Distribution of cumulative confirmed cases of Bundibugyo virus disease in the Democratic Republic of the Congo, as of 23 September Ituri continues to be the epicentre of the outbreak, accounting for 6032 confirmed cases since the start of the outbreak, including 868 new confirmed cases reported in the previous 21 days, as of 23 September. North Kivu is the second most affected province, with a cumulative number of 1480 confirmed cases, including 567 reported in the last 21 days, as of 23 September. North Kivu province continues to report the highest CFR (59.7%) observed in this outbreak; and investigations are ongoing to better understand the factors contributing to this elevated mortality rate. In Ituri, case incidence continues to decline gradually from the peak observed in mid-August, although transmission remains at elevated levels. North Kivu, in contrast, has experienced a substantial increase in incidence, reaching its highest reported level in mid-September, followed by a decline in recent reporting days. Haut-Uélé continues to demonstrate sustained transmission, albeit at levels below the peak recorded in late August, while Tshopo is showing renewed transmission activity following a period of low incidence. In Bas-Uélé, transmission remains sporadic, whereas no recent evidence of transmission has been reported in Sud-Kivu. Sud Ubangi is the seventh province to report a confirmed case of BVD, with one case that was reported on 10 September (Figure 2). The number of individuals requiring follow-up as contact has also risen considerably with the expansion of the outbreak. As of 23 September, 83.4% of identified contacts were successfully monitored during the previous 24 hours with 26 980 contacts seen out of 32 342 requiring follow up. The large volume of contacts under surveillance highlights the extent of potential exposure within affected communities and the substantial demands placed on response operations. The response is being implemented in a challenging humanitarian environment, where conflict, insecurity, displacement, and limited access to basic services continue to affect outbreak control. These constraints continue to hamper surveillance, case finding, contact tracing, infection prevention and control, and timely access to appropriate care, thereby limiting the overall effectiveness of response activities. Figure 2: Number of confirmed Bundibugyo virus disease cases in the Democratic Republic of the Congo, by date of notification, as of 23 September 2026 Figure 3: Number of deaths among confirmed Bundibugyo virus disease cases in the Democratic Republic of the Congo by date of notification, as of 23 September 2026.

Since the publication of the previous Disease Outbreak News on 28 August 2026, additional confirmed cases and deaths of Bundibugyo virus disease (BVD) have been reported only in the Democratic Republic of the Congo. As of 7 September 2026, a cumulative total of 6778 confirmed cases has been reported: 6757 in the Democratic Republic of the Congo (including two cases diagnosed in the Democratic Republic of the Congo and subsequently treated in Germany), 20 cases in Uganda and one case in France. Overall, 3269 deaths have been reported, including two in Uganda. As of 7 September, at least 1611 patients have recovered, including 1590 in the Democratic Republic of the Congo, 18 in Uganda, two in Germany and one in France. The sustained level of transmission in the Democratic Republic of the Congo continues to pose a risk of cross-border spread. Health screening and surveillance activities remain operational at airports, ports, and official land border crossings; however, travel through informal crossing routes persists and may facilitate virus exportation, importation, and subsequent transmission. In this context, strengthened cross-border coordination, together with ongoing surveillance and preparedness efforts, remains critical to limiting further regional spread and supporting an effective public health response. Figure 1. Distribution of cumulative confirmed cases of Bundibugyo virus disease in the Democratic Republic of the Congo, as of 7 September Democratic Republic of the Congo Since the previous Disease Outbreak News was published on 28 August 2026, an additional 963 confirmed cases, including 481 confirmed deaths, have been reported in the Democratic Republic of the Congo. While part of this increase may be attributable to strengthened surveillance activities, enhanced laboratory testing, improved diagnostic capacity, and reconciliation of previously unreported data, the continued growth in both cases and deaths also reflects sustained community transmission and significant geographic expansion of the outbreak. As of 7 September, the Democratic Republic of the Congo has reported a total of 6757 confirmed cases, including 3267 deaths (CFR 48.3%). A total of 1590 patients have recovered to date. Confirmed cases have been reported from 61 health zones (HZ) across six provinces, with 51 HZ from five provinces reporting at least one case in the last 21 days. Ituri remains the most affected province, with 28 of its 36 health zones reporting cases, followed by North Kivu (16/34), Tshopo (7/23), Haut-Uélé (6/13), Bas-Uélé (3/11), and South Kivu (1/34). No new cases have been reported from South Kivu province since 29 May 2026. Kayna HZ in North Kivu province is the most recently affected area. As of 7 September, 71 new confirmed cases had been reported in the preceding 24 hours from 17 health zones located in Ituri, North Kivu, and Haut-Uélé provinces. Ituri continues to be the epicentre of the outbreak, accounting for 5406 confirmed cases since the start of the outbreak, including 1114 new confirmed cases reported in the previous 21 days, as of 7 September. North Kivu is the second most affected province, with a cumulative number of 1066 confirmed cases, including 453 reported in the last 21 days, as of 7 September. One of the highest CFR (65.4%) observed in this outbreak has been reported from North Kivu province; and investigations are ongoing to better understand the factors contributing to this elevated mortality rate. The number of individuals requiring follow-up as contact has also risen considerably with the expansion of the outbreak. As of 7 September, 85.3% of identified contacts were successfully monitored during the previous 24 hours with 21 359 contacts seen out of 24 719 requiring follow up. The large volume of contacts under surveillance highlights the extent of potential exposure within affected communities and the substantial demands placed on response operations. The outbreak continues to unfold within a complex humanitarian setting characterized by insecurity, armed conflict, and widespread population displacement. More than 26 million people are experiencing acute food insecurity, while approximately one million internally displaced persons reside in Ituri Province alone. Ongoing insecurity and displacement limit access to healthcare and essential services, constrain the ability of response teams to reach affected areas, and impede surveillance, case investigation and contact tracing activities. Overcrowding, limited water, sanitation and hygiene services, and restricted access to healthcare in mining communities, informal settlements and sites for internally displaced persons further undermine early case detection, infection prevention and control measures, and the provision of timely care. These conditions also reduce the effectiveness of response interventions and outreach efforts. Figure 2: Number of confirmed Bundibugyo virus disease cases in the Democratic Republic of the Congo, by date of notification, as of 7 September 2026 Figure 3: Number of deaths among confirmed Bundibugyo virus disease cases in the Democratic Republic of the Congo by date of notification, as of 7 September 2026.

Since the previous Disease Outbreak News was published on 14 August 2026, additional confirmed cases and deaths of BVD have been reported only in the Democratic Republic of the Congo. Cumulatively as of 26 August 2026, 5815 confirmed cases have been reported: 5794 in the Democratic Republic of the Congo (including two cases diagnosed in the Democratic Republic of the Congo and subsequently treated in Germany), 20 in Uganda and one in France. A total of 2788 deaths have been reported, including two in Uganda. As of 26 August, at least 1314 patients have recovered, including 1293 in the Democratic Republic of the Congo, 18 in Uganda, two in Germany and one in France. As of 27 August, the 42-day enhanced monitoring period, as per international guidance, has been completed in both France and Uganda. The continuing intensity of transmission in the Democratic Republic of the Congo means that the risk of further exportation across international borders remains. Entry and exit health screening and surveillance measures are in place at airports, ports and official land border crossings; however, movement through informal border crossing routes may occur, presenting an ongoing risk of virus exportation, importation and onward transmission. Therefore, cross‑border collaboration, and sustained surveillance and preparedness are essential to prevent further regional spread and ensure an effective public health response. On 27 August, vaccination of health care workers using the Ervebo vaccine was initiated in the Democratic Republic of the Congo in some areas, including in Kisangani, Tshopo province. Although Ervebo is a safe vaccine, and effective against Ebola virus disease, it is not known whether it provides protection against the Bundibugyo virus in humans. Thus, starting a clinical trial of the vaccine, alongside this wider use, is key to provide important new evidence and inform future use of the vaccine. The second IHR Emergency Committee meeting regarding the epidemic of Ebola Bundibugyo virus disease in the Democratic Republic of the Congo took place on 18 August. Following the advice of the Committee, the Director-General agreed that the ongoing outbreak remains a Public Health Emergency of International Concern, and issued updated temporary recommendations to countries. Figure 1. Distribution of cumulative confirmed cases of Bundibugyo virus disease in the Democratic Republic of the Congo, as of 26 August Democratic Republic of the Congo Since 14 August 2026 when the last Disease Outbreak News was published, an additional 1129 confirmed cases, including 602 confirmed deaths, have been reported in the Democratic Republic of the Congo. Although part of this increase likely reflects expanded surveillance, enhanced laboratory testing, improved diagnostic capacity, and periodic data backlog reconciliation, the sustained rise in number of cases and deaths are the result of continued transmission and substantial outbreak expansion. As of 26 August 2026, a total of 5794 confirmed cases, including 2786 deaths (CFR 48.1%), have been reported in the Democratic Republic of the Congo. To date, 1293 patients have recovered. Cases have been reported from 60 health zones (HZ) across six provinces. Ituri has 28 health zones affected out of 36, followed by North Kivu (15/34), Haut-Uélé (6/13), Tshopo (7/23), South Kivu (1/34) and Bas Uélé (3/11). The most recently affected province, Bas-Uélé, started reporting cases since 12 August. The most recently affected health zones are Biena and Manguredjipa in North Kivu province. As of 26 August, of the 60 affected health zones, 81 new confirmed cases were reported in the last 24 hours from 19 health zones in Ituri, North Kivu, Haut-Uélé, and Tshopo provinces. Ituri remains the epicentre of the outbreak, with 4802 confirmed cases reported since the start of the outbreak, including 52 new confirmed cases reported in the last 24 hours, as of 26 August. Nord-Kivu is the second most affected province, with a cumulative number of 775 confirmed cases, including 22 reported in the last 24 hours, as of 26 August. The highest CFR (68%) in this outbreak has been reported from North Kivu province; the reasons for this high CFR are under investigation. The number of individuals requiring contact monitoring has also increased substantially as the outbreak has expanded. As of 26 August, the proportion of contacts followed up in the last 24 hours is at 82.3% (22 091 seen out of 26 850 to follow up). The large number of contacts reflects the scale of potential exposure within affected communities. The outbreak is unfolding in a conflict-affected humanitarian context marked by insecurity, armed violence, and large-scale displacement. More than 26 million people face acute food insecurity, and an estimated one million internally displaced people live in Ituri Province alone. Insecurity and displacement disrupt access to health care and essential services, restrict access for response teams, and impede surveillance, case investigation and contact follow-up. Overcrowding, limited water, sanitation and hygiene services, and restricted access to healthcare in mining communities, informal settlements and sites for internally displaced people further hinder early detection, infection prevention, and appropriate care. These conditions also make it harder to implement response measures consistently and to reach affected populations. Figure 2: Number of confirmed Bundibugyo virus disease cases in the Democratic Republic of the Congo, by date of notification, as of 26 August 2026 Figure 3: Number of deaths among confirmed Bundibugyo virus disease cases in the Democratic Republic of the Congo by date of notification, as of 26 August 2026 Between 18 May and 28 August 2026, enhanced public health intelligence conducted by WHO identified 76 Ebola-related signals across 23 countries and territories, supporting rapid verification, risk assessment and information sharing with national authorities through IHR National Focal Points. Most signals, 92% (70/76), including suspected cases among travellers and health-care workers and reports circulating in public sources, were subsequently ruled out through investigation and laboratory testing. The remaining six were confirmed as Ebola events.

Since the previous Disease Outbreak News was published on 1 August 2026, additional confirmed cases and deaths of BVD have been only reported in the Democratic Republic of the Congo. Cumulatively as of 12 August 2026, 4686 confirmed cases have been reported: 4665 in the Democratic Republic of the Congo (including two cases diagnosed in the Democratic Republic of the Congo and subsequently treated in Germany), 20 in Uganda and one in France. A total of 2186 deaths have been reported, including two in Uganda. As of 12 August, at least 986 patients have recovered including 965 in the Democratic Republic of the Congo, 18 from Uganda have recovered, two in Germany and one from France. As reported in the Disease Outbreak News published on 1 August 2026, with more confirmed cases than the 2018-2020 outbreak, which reported 3,317 cases, this outbreak now represents the largest Ebola disease outbreak ever documented in the country. Figure 1. Distribution of cumulative confirmed cases of Bundibugyo virus disease in the Democratic Republic of the Congo as of 12 August Democratic Republic of the Congo Since 1 August 2026 when the last Disease Outbreak News was published, an additional 1060 confirmed cases, including 597 confirmed deaths, have been reported in the Democratic Republic of the Congo. The increase is in part due to strengthened surveillance activities, enhanced laboratory testing, and diagnostic capacity. However, most of the increase reflects the expansion of the outbreak. As of 12 August 2026, a total of 4665 confirmed cases, including 2184 deaths (CFR 46.8%), have been reported in the Democratic Republic of the Congo. To date, 965 patients have recovered. Cases have been reported from 54 health zones (HZ) across six provinces: Ituri (28/36 HZ), North Kivu (12/34 HZ), South Kivu (1/34 HZ), Haut-Uélé (6/13 HZ), Tshopo (6/23 HZ), and Bas- Uélé (1/11 HZ). The most recently affected province, Bas-Uélé, reported one confirmed case in Buta Health Zone. The case had a travel history to Haut-Uélé, with symptom onset on 4 August. As of 12 August, of the 54 affected health zones, 100 new confirmed cases were reported in the last 24 hours from 22 health zones in all affected provinces except for Sud-Kivu. The highest number of new cases in the last 24 hours (67) was reported from Ituri province followed by Nord-Kivu (25). Ituri remains the most affected province, accounting for 85% (3979/4665) of all confirmed cases and 79% (1726/2184) of reported deaths nationwide. As of 12 August, the proportion of contacts followed up in the last 24 hours is at 84.2% (17 460 seen out of 20 740 to follow up). As of 9 August, infections among health workers continue, with at least 155 confirmed cases, including 45 deaths (CFR: 29%) and 68 recoveries since beginning of the outbreak. These infections highlight ongoing occupational exposure risks, persistent challenges in implementing infection prevention and control (IPC) in health-care facilities—especially outside of the designated Ebola treatment centres which have more established protocols and access to supplies--and continued exposure risk in the community. The outbreak is taking place amid a severe humanitarian crisis and ongoing insecurity, characterized by large-scale population displacement, significant population mobility, and constrained access to critical services, including health care, safe water, food, shelter, and protection. Response efforts in the affected provinces have been hindered by insecurity and attacks on health facilities, which have curtailed access for response teams, discouraging potential patients from seeking care, disrupting surveillance and response activities and increasing the risk of undetected transmission. Since the declaration of the Ebola public health emergency of international concern (PHEIC) on 17 May 2026, 12 attacks on health care have been recorded, with additional reports under verification. These challenges underscore the importance of community-centred response efforts led by local authorities and trusted community leaders. Figure 2: Number of confirmed cases (n = 4665), in the Democratic Republic of the Congo, by date of reporting and as of 12 August 2026 * Note that the large number of reported cases on 22 July represents the completion of a data reconciliation exercise, including cases that occurred earlier in the outbreak, rather than newly recorded cases. Figure 3: Number of deaths among confirmed cases (n = 2184), in the Democratic Republic of the Congo, by date of reporting, as of 12 August 2026 * Note that the large number of reported deaths on 22 July represents the completion of a data reconciliation exercise, including deaths that occurred earlier in the outbreak, rather than newly recorded deaths.

Since the previous Disease Outbreak News was published on 17 July 2026, additional confirmed cases and deaths have been reported only in the Democratic Republic of the Congo. Cumulatively, 3626 confirmed cases have been reported: 3605 in the Democratic Republic of the Congo (including two cases diagnosed in the Democratic Republic of the Congo and subsequently treated in Germany), 20 in Uganda and one in France. A total of 1589 deaths have been reported, including two in Uganda. As of 30 July, at least 654 patients have recovered including 651 in the Democratic Republic of the Congo,18 from Uganda, two in Germany and one in France. This outbreak is now the largest recorded Ebola disease outbreak in the country, surpassing the previous largest outbreak, which occurred from 2018 to 2020, and resulted in 3317 confirmed cases. Figure 1. Distribution of cumulative confirmed cases of Bundibugyo virus disease in the Democratic Republic of the Congo as of 30 July Democratic Republic of the Congo Since 17 July 2026 when the last Disease Outbreak News was published, an additional 1481 confirmed cases, including 759 confirmed deaths, have been reported in the Democratic Republic of the Congo. The increase is in part due to expansion of surveillance activities, enhanced laboratory testing, and diagnostic capacity. However, most of the increase reflects the expansion of the outbreak. As of 30 July 2026, a total of 3605 confirmed cases, including 1587 deaths (CFR 44%), have been reported in the Democratic Republic of the Congo. To date, 651 patients have recovered. Cases have been reported from 49 health zones (HZ) across five provinces: Ituri (28/36 HZ), North Kivu (11/34 HZ), South Kivu (1/34 HZ), Haut- Uélé (5/13 HZ) and Tshopo (4/23 HZ).[1] An additional HZ, Wanie-Rukula in Tshopo, is awaiting data harmonisation at the health province level. Of the 49 affected health zones, the outbreak remains active in 33, with confirmed cases reported within the past seven days. During this period, 641 confirmed cases, including 282 confirmed deaths, were reported. Ituri remains the most affected province, accounting for 88% (3176/3605) of all confirmed cases and 82.6% (1311/1587) of reported deaths nationwide. Within the province, the highest number of confirmed cases have been reported from Bunia (880 cases), Rwampara (627 cases), Mongbwalu (541 cases), Nizi (377 cases), Lita (131 cases), and Nyankunde (114 cases) health zones. As of 30 July, 17 863 contacts have been identified and are under follow-up across Ituri (11 638), North Kivu (5667), Haut-Uélé (458) and 65 in Tshopo. Of these, 13 455 contacts were under active follow-up, corresponding to follow-up rates of 75.5% in Ituri, 74.6% in North Kivu, 80.6% in Haut-Uélé, and 66.2% in Tshopo. Previously identified contacts in South Kivu have completed the required 21-day follow-up period. Infections among health workers continue, with 151 confirmed cases, including 44 deaths (CFR: 29%) and 68 recoveries. These infections highlight ongoing occupational exposure risks, persistent challenges in implementing infection prevention and control (IPC) in health-care facilities, and continued exposure risk in the community. The outbreak is occurring in a complex humanitarian and conflict-affected setting, characterized by population displacement, high population mobility, and limited access to essential services, including health care, clean water, food, shelter, and protection. These conditions increase the risk of disease transmission, including in overcrowded sites for internally displaced persons (IDPs). Insecurity and attacks affecting health facilities have hampered response operations in affected provinces, by restricting access for response teams, disrupting surveillance and response activities and increasing the risk of undetected transmission. These challenges underscore the importance of community-centred response efforts led by local authorities and trusted community leaders. Figure 2: Number of confirmed cases (n = 3605), in the Democratic Republic of the Congo, by date of reporting, as of 30 July 2026 * Note that the large number of reported cases on 22 July represents the completion of a data reconciliation exercise, including cases that occurred earlier in the outbreak, rather than newly recorded cases. Figure 3: Number of deaths among confirmed cases (n = 1587), in the Democratic Republic of the Congo, by date of reporting, as of 30 July 2026. * Note that the large number of reported deaths on 22 July represents the completion of a data reconciliation exercise, including deaths that occurred earlier in the outbreak, rather than newly recorded deaths.

Since the previous Disease Outbreak News was published on 3 July 2026, the number of confirmed cases and deaths has increased substantially in the Democratic Republic of the Congo. In total, 2145 confirmed cases have been reported: 2124 in the Democratic Republic of the Congo (including two cases with diagnosis in the Democratic Republic of the Congo and subsequent treatment in Germany), 20 in Uganda and one in France. A total of 830 deaths has been reported, including two in Uganda. To date, at least 410 patients have recovered, including 390 in the Democratic Republic of the Congo, 18 in Uganda, one in France, and one in Germany. Figure 1. Distribution of cumulative confirmed cases of Bundibugyo virus disease in the Democratic Republic of the Congo as of 15 July and Uganda as of 17 July Democratic Republic of the Congo Since 3 July 2026, an additional 664 confirmed cases, including 376 confirmed deaths, have been reported in the Democratic Republic of the Congo. The increase is in part due to the scale-up of surveillance activities, testing, and diagnostic capacities. As of 15 July 2026, a total of 2124 confirmed cases, including 828 deaths (crude case fatality ratio [CFR] 39%) have been reported in the Democratic Republic of Congo. So far, 390 patients have recovered. Cases have been reported from 46 health zones (HZ) across five provinces: Ituri (27/36 HZ), North Kivu (11/34 HZ), South Kivu (1/34 HZ), Haut-Uele (4/13 HZ) and Tshopo (3/23 HZ). Of the 46 affected health zones, the outbreak remains active in 38 health zones, which have reported cases within the past 21 days. The remaining health zones have not reported any new cases during this period. In the past 21 days, 969 confirmed cases, including 524 confirmed deaths, have been reported. Ituri remains the most affected province, accounting for 89.6% (1904/2124) of all confirmed cases and 83.6% (692/828) of all reported deaths nationwide. Within the province, the highest number of confirmed cases have been reported from Bunia (570 cases), Rwampara (418 cases), Mongbwalu (347 cases), Nizi (148 cases), and Nyankunde (99 cases) health zones. As of 15 July, 12 693 contacts have been identified and are under follow-up across Ituri (10 183), North Kivu (2360) and Tshopo (150). Of these, 10 195 contacts have been followed up, corresponding to follow-up rates of 78.1% in Ituri, 50.0% in Tshopo and 91.7% in North Kivu. Previously listed contacts in South Kivu have completed their 21-day followup. In addition, 107 contacts of the case reported in France have been listed and are under follow-up in Kinshasa. Infections among health workers continued to increase, with 119 confirmed cases, 61 recoveries and 36 deaths reported among health workers, corresponding to a CFR of 30.3%. This highlights persistent occupational exposure risks, inadequate infection prevention and control (IPC) implementation in health facilities, and exposure risk in the community. The outbreak continues in a complex humanitarian and conflict-affected environment, characterized by highly mobile and often displaced populations, many of whom have limited access to basic services, including food, clean water, shelter, health care and protection. These conditions increase the risk of transmission, particularly in overcrowded sites for internally displaced people. Security incidents affecting health facilities, have created additional operational challenges in affected provinces, including restricted access for response teams, disruption of surveillance and response activities and an increased risk of undetected transmission. These conditions underscore the need for response efforts to be led by local leaders and anchored in communities. Figure 2: Number of confirmed cases (n = 2124), in the Democratic Republic of the Congo, by date of reporting and as of 15 July 2026 Figure 3: Number of deaths among confirmed cases (n = 828), in the Democratic Republic of the Congo, by date of reporting and as of 15 July 2026. NB: Newly reported confirmed cases/deaths may be part of the backlog of samples and therefore not necessarily newly acquired infections. Uganda The last confirmed case was reported to be identified on 21 June 2026. As of 14 July 2026, a cumulative total of 20 confirmed cases have been reported, including two deaths in imported cases (reported on 15 May and 5 June) and one probable case resulting in death. Of the confirmed cases, 15 were imported cases and five were secondary cases among contacts and health workers linked to imported cases from the Democratic Republic of the Congo. All cases were reported in Kampala District. To date, no community transmission has been in Uganda. Exposure risks have been associated with health-care settings and cross-border movements. Following case reclassification, the number of affected healthcare workers was revised from five to four. In total, 18 recoveries have been reported. Of the 831 contacts listed as of 28 June, 821 contacts have completed their 21-day follow-up period as of 14 July. The most recent case was discharged from the treatment centre on 16 July after two negative tests results. This marks the start of the 42-day countdown period (twice the maximum incubation period) to ensure surveillance activities continue to be implemented and detect any cases that were missed before the declaration of the end of the outbreak. Given the ongoing outbreak in the Democratic Republic of the Congo, the risk of importation still exists. Figure 4: Number of confirmed cases (n = 20), in Uganda by date of reporting and as of 17 July 2026 France No additional BVD cases have been reported in France since the previous update. The imported confirmed BVD case reported on 24 June recovered and was discharged from the healthcare facility on 4 July after two negative PCR test results. No secondary transmission has been identified among the five low-risk flight contacts placed under precautionary quarantine. These contacts completed their follow-up period on 14 July. French authorities have been monitoring these individuals in coordination with relevant regional public health authorities as well as with the National IHR Focal Points of Belgium and the Netherlands who conducted an individual risk assessment. None of the contacts developed symptoms, and no addtional at-risk individuals have been identified. Germany A physician from the United States working in the Democratic Republic of the Congo, was medically evacuated and treated in Germany in May 2026. The patient recovered and was discharged. No secondary cases were reported. A second United States citizen, a humanitarian worker, tested positive for Bundibugyo virus in the Democratic Republic of Congo in July 2026 and was medically evacuated to a university hospital in Frankfurt/Main, Germany. The patient is reported to be in stable condition.

Since the last Disease Outbreak News was published on 19 June 2026, the number of confirmed cases and deaths have increased rapidly in the Democratic Republic of the Congo. In total, 1481 confirmed cases; 1460 from the Democratic Republic of the Congo, 20 from Uganda and one from France (linked to DRC); and 454 deaths including two from Uganda, have been reported. At least 229 patients have recovered from the disease; 213 patients from the Democratic Republic of the Congo and 16 patients from Uganda. Figure 1. Distribution of confirmed cases of Bundibugyo virus disease in the Democratic Republic of the Congo as of 1 July and Uganda as of 2 July Democratic Republic of the Congo Since 19 June when the last Disease Outbreak News was published, an additional 564 confirmed cases, including 220 confirmed deaths, have been reported from the Democratic Republic of the Congo. The increase is in part due to the scale up of surveillance activities, testing and diagnostic capacities. As of 1 July 2026, a total of 1460 confirmed cases including 452 deaths (crude case fatality ratio [CFR] 30.9%) have been reported from the Democratic Republic of Congo. So far, 213 patients have recovered. Cases have been reported from 36 health zones (HZ) from Ituri (24/36 HZ), North Kivu (11/35 HZ) and South Kivu provinces (1/34 HZ).[1] To date, 102 confirmed cases including 25 deaths have been reported among health and care workers. Of the 36 affected health zones, the outbreak remains active in 21 health zones from where cases have been reported in the past 21 days. The remaining health zones have not reported any new cases during this period. In the past 21 days, 838 confirmed cases, including 314 confirmed deaths, have been reported. Ituri Province remains the most affected, accounting for 91.3% (1333/1460) of all confirmed cases and 84% (380/452) of all reported deaths nationwide. Within the province, the highest number of confirmed cases have been reported from Bunia (416 cases), Rwampara (308 cases), Mongbwalu (270 cases), Nyankunde (95 cases), and Nizi (65 cases) health zones. As of 1 July, the outbreak has spread to three additional health zones in the province. Following epidemiological investigations, three confirmed cases with travel history from Nia Nia health zone in Ituri province have been reported on 30 June in Wamba health zone in Haut Uele Province and Kisangani in Tshopo province. These cases have been reported under Nia Nia health zone. Response activities, including contact tracing and follow-up, are ongoing in both provinces. Of the total confirmed cases, 17 are yet to be assigned to a specific health zone.As of 1 July, 10 821 contacts have been identified and are under follow-up across Ituri (8376), and North Kivu (2445). Of these, 8954 contacts have been followed up, corresponding to follow-up rates of 83.2% in Ituri, and 81% in North Kivu. Previously listed contacts from South Kivu province have completed 21 days of follow up. In addition, 107 contacts of the case reported in France have been listed and are under follow up in Kinshasa. The outbreak is unfolding in a complex humanitarian and conflict-affected environment, characterized by highly mobile and often displaced populations, often lacking access to basic services, including food, clean water, shelter, healthcare and protection which poses an increased risk of transmission to the populations living in overcrowded internally displaced camps. These dynamics, combined with increasing security-related incidents affecting health facilities, have posed additional operational challenges in affected provinces, such as constrained access for response teams, disrupted surveillance and response activities, and heightened risk of undetected transmission. These conditions underscore the need for response efforts to be led by local leaders and anchored in communities. Figure 2: Number of confirmed cases (n = 1460), in the Democratic Republic of the Congo, by date of reporting, as of 1 July 2026 Figure 3: Number of deaths among confirmed cases (n = 452), in the Democratic Republic of the Congo, by date of reporting, as of 1 July 2026. NB: Newly reported confirmed cases/deaths may be part of the backlog of samples and therefore not necessarily newly acquired infections. Uganda The last confirmed case was reported to be identified on 21 June 2026. As of 2 July 2026, a cumulative of 20 confirmed cases including two deaths in imported cases (reported on 15 May and 5 June), and one probable case who has died, have been reported. Of the confirmed cases, 15 are imported cases, while five are secondary cases among contacts and health workers with links to imported cases from the Democratic Republic of the Congo. The cases have been reported in two districts, Kampala and Wakiso, both part of the Kampala Metropolitan Area. To date, there has been no documented community transmission in Uganda. Exposure risks are associated with healthcare settings and cross-border movements. Following case reclassification, the number of affected healthcare workers was revised from five to four. In total, 16 recoveries have been reported to date. Of the 831 contacts listed as of 28 June, 821 contacts have completed their 21-day follow-up period as of 2 July. Figure 4: Number of confirmed cases (n = 20), in Uganda by date of reporting, as of 2 July 2026 France: On 24 June 2026, French authorities notified WHO of a laboratory-confirmed case of Ebola disease caused by Bundibugyo virus in a middle-aged male medical doctor returning from the Democratic Republic of the Congo. The patient had been deployed for five weeks in Ituri Province, where he was involved in the care of patients with BVD. Upon arrival at Charles de Gaulle Airport on 23 June 2026, the patient self-reported symptoms to airport health authorities, prompting immediate isolation and referral to a designated high-containment healthcare facility. At the time of reporting, the patient was clinically stable and had no fever, with no reported vomiting, diarrhoea, or haemorrhagic manifestations during travel. PCR testing detected Bundibugyo virus. Comprehensive contact tracing has been initiated in the Democratic Republic of the Congo and in France.

On 2 May 2026, in accordance with the International Health Regulations (2005) (IHR), WHO received a notification from the National IHR Focal Point (NFP) of the United Kingdom of a cluster of severe acute respiratory illness aboard the Netherlands-flagged cruise ship M/V Hondius, with further details rapidly notified authorities in the Netherlands and South Africa. As of 2 July, a total of 13 cases (12 confirmed and one probable case), including three deaths (two confirmed and one probable), have been reported globally linked to the cruise ship. The case fatality ratio for this outbreak to date is 23%. Since the last Disease Outbreak News was published on 28 May 2026, ANDV infection was laboratory confirmed in a probable case in Tristan da Cunha who developed signs and symptoms after disembarkation from the cruise ship. The early detection and isolation of the case prevented further transmission of the virus, but the limited diagnostic capacities on the island delayed the confirmation of the case until a sample was shipped and tested in the United Kingdom. The patient has recovered and has been discharged. Among the confirmed cases admitted to hospital, eight have recovered and been discharged, while two, one in South Africa and one in France, continue to be hospitalized. All 13 cases are among people who travelled on board the M/V Hondius. Figure 1. Epidemiological curve of Andes hantavirus cases (n = 13) reported to WHO as of 2 July 2026. Nine of the reported cases were males, and four were females. The median age was 65-years-old (IQR 56-70), similar to the median age of the passengers onboard the ship (Figure 2). The ages of the three deceased cases were 69, 70 and 79-years-old. Figure 2. Age and sex distribution of Andes hantavirus cases (n = 13) reported to WHO as of 2 July 2026. Currently available information suggests that infection of initial cases was likely acquired on land prior to embarkation, although the exact source and route of exposure remain undetermined, with subsequent human-to-human transmission occurring aboard the vessel. Investigations remain underway to establish the circumstances and source of the outbreak, including genomic sequencing of ANDV samples from surveillance cases in Chile and Argentina, and will be published as soon as these are available. This outbreak was managed through a coordinated international response, which included comprehensive epidemiological investigations, case isolation and clinical management, medical evacuations, laboratory testing, repatriation of passengers and crew from the ship and international contact tracing, as well as quarantine and monitoring measures. Contact identification and follow-up of contacts of hantavirus cases linked to the cruise ship has been conducted in 33 countries and overseas territories. This included passengers and crew onboard the ship, contacts of the case on Tristan da Cunha, contacts from two different international flights, healthcare workers and airport crew who assisted cases before the detection of the outbreak. As of 2 July 2026, 317 high-risk contacts have completed quarantine and monitoring by local health authorities in the countries and territories where they were repatriated, evacuated or identified. Some 336 low-risk contacts completed self-monitoring in line with the updated guidance on management of contacts of Andes virus (ANDV) cases from the MV Hondius cruise ship published on 17 May 2026.

On 11 June 2026, WHO was informed of a laboratory-confirmed case of Nipah virus infection reported in Kozhikode district, Kerala State. Initial positive results were obtained through PCR testing at local laboratories and were subsequently confirmed by RT‑PCR at the National Institute of Virology, Pune. The case is an adult male resident of Kozhikode district. He developed symptoms on 30 May 2026 and was admitted to hospital on 10 June 2026. The clinical presentation was primarily neurological, without reported respiratory symptoms prior to intubation. The patient is on ventilatory support in the ICU. Following confirmation of the case, extensive contact tracing was initiated. As of 18 June 2026, a total of 104 contacts had been identified, including four very high-risk, 14 high-risk, and 86 low-risk contacts. Among these, 45 are health and care workers. All contacts are under active monitoring with regular follow-up, and no secondary cases have been reported to date. This event follows a pattern of recurrent Nipah virus outbreaks in Kerala, including in Kozhikode district, since the first outbreak was reported in 2018. Additional outbreaks occurred in 2019, 2021, 2023, 2025, and 2026 according to the NCDC Communicable Disease Alert.

Globally, in 2025 and early 2026, sylvatic yellow fever (YF) transmission in high-risk areas has been strongly influenced by rainfall, temperature and mosquito ecology. In 2025, the epidemiological situation was defined by sustained transmission in Africa and a notable rise in the Americas, including spread into lower‑risk zones. African Region: Twenty-six countries in the WHO African Region and one in the WHO Eastern Mediterranean Region are considered high-risk for YF as per EYE strategy classification. Of these 27 countries, 26 have introduced the yellow fever vaccine in their routine immunization schedule, however coverage in many countries remains below target with an average coverage of 65% across the region in 2024. Since 2023, eight countries with no recent activity have detected new cases, indicating viral circulation in areas with low vaccination coverage and limited surveillance capacity. In 2025, two outbreaks were recorded (in Angola and in Central African Republic) along with several events that required emergency vaccination. From January to May 2026, 16 confirmed cases were reported in three countries (Burkina Faso, Central African Republic and Cameroon), with additional suspected cases under investigation reported in five countries (Angola, Côte d’Ivoire, Gabon, Ghana, and Nigeria). Most infections are linked to ongoing sylvatic transmission spilling over into rural, under‑immunized communities. Recurrent events are straining health systems and increasing the risk of cross‑border spread. Region of the Americas: All 13 countries at high-risk for YF as per EYE strategy classification include the vaccine in their routine immunization, but coverage varies widely. After limited activity in 2024, transmission expanded sharply in 2025, including into areas that had not reported cases for decades. The region recorded 241 cases and 100 deaths between late 2024 and early 2025, an eightfold increase from the previous year. From January to May 2026, six countries (Bolivia, Brazil, Colombia, Ecuador, Peru, and Venezuela) reported 79 confirmed cases, with Colombia most affected due to sylvatic exposure and travel by unvaccinated visitors. Ecological suitability for mosquito vectors, uneven vaccination coverage, increased human mobility, and the expansion of urban areas into forested environments continue to facilitate viral transmission. Other Regions: In regions outside Africa and the Americas, the risk of YF is primarily associated with imported cases, as no established local transmission cycles are present. Many countries require proof of vaccination for travellers from at‑risk areas. No imported cases were detected in 2025–2026, but ongoing transmission elsewhere, expanding vector habitats, rapid urbanization, and high international mobility mean the risk of introduction persists. The impact of any imported case would depend on rapid detection and the ability to respond effectively in areas where competent mosquito vectors are present.

Since the last Disease Outbreak News was published on 13 June 2026, the number of confirmed cases and deaths have increased rapidly in the Democratic Republic of the Congo. In total, 915 confirmed cases; 896 from the Democratic Republic of the Congo and 19 from Uganda; and 234 deaths including two from Uganda, have been reported. At least 88 patients have recovered from the disease; 78 patients from the Democratic Republic of the Congo and 10 patients from Uganda. Figure 1. Distribution of confirmed cases of Bundibugyo virus disease in the Democratic Republic of the Congo, as of 17 June; and Uganda, as of 18 June Democratic Republic of the Congo Since 13 June when the last Disease Outbreak News was published, an additional 220 confirmed cases, including 96 confirmed deaths, have been reported from the Democratic Republic of the Congo. The increase is in part due to the scale up of testing and diagnostic capacities, enabling testing of the backlog of previously collected samples. As of 17 June 2026, a total of 896 confirmed cases including 232 deaths (case fatality ratio [CFR] 26%) have been reported from the Democratic Republic of Congo. The reported CFR is likely an underestimation, as many deaths that occurred before the outbreak declaration remain under investigation. So far, 78 patients have recovered. Cases have been reported from 33 health zones (HZ) from Ituri (21/36 HZ), North Kivu (11/35 HZ) and South Kivu provinces (1/34 HZ)[1]. The outbreak remains concentrated in Ituri Province, which accounts for 91.1% (817) of the confirmed cases with a CFR of 22.7% (186/817). The highest number of confirmed cases in Ituri Province are reported from Bunia (247 cases), Rwampara (195 cases), Mongbwalu (189 cases), and Nyankunde (68 cases) health zones. So far, the epicentre of the outbreak remains Ituri, with new confirmed cases reported from an additional four health zones as of 17 June. However, the identification of cases in some of these newly reporting health zones may reflect previously undetected transmission rather than recent introduction of the virus. Epidemiological investigations indicate that transmission had likely been occurring in some of these areas for several weeks before the first cases were confirmed and reported. Of the total confirmed cases, 17 are awaiting distribution by health zone. As of 17 June, 6367 contacts have been identified and are under follow-up across Ituri (4659), North Kivu (1628), and South Kivu (80) provinces. Of these, 4525 contacts have been followed up, corresponding to follow-up rates of 70.8% in Ituri, 70.5% in North Kivu, and 100% in South Kivu. The outbreak is unfolding in a complex humanitarian and conflict-affected environment, characterized by highly mobile and often displaced populations, often lacking access to basic services, including food, clean water, shelter, healthcare and protection which poses an increased risk to the populations living in overcrowded internally displaced camps. These dynamics, combined with increasing security-related incidents affecting health facilities, have posed additional operational challenges in affected provinces, such as constrained access for response teams, disrupted surveillance and response activities, and heightened risk of undetected transmission. These conditions underscore the need for response efforts to be led by local leaders and anchored in communities. Figure 2: Number of confirmed cases (n = 896), in the Democratic Republic of the Congo, by date of reporting as of 17 June 2026 Figure 3: Number of deaths among confirmed cases (n = 232), in the Democratic Republic of the Congo, by date of reporting as of 17 June 2026 NB: Newly reported confirmed cases/deaths may be part of the backlog of samples and therefore not necessarily newly acquired infections. Uganda The last confirmed case was reportedly identified on 5 June 2026. As of 18 June 2026, a cumulative of 19 confirmed cases including two deaths in imported cases (reported on 15 May and 5 June), and one probable case who has died, have been reported. Of the confirmed cases, 14 cases are imported and five are secondary transmission among contacts and health workers following cases imported from the Democratic Republic of the Congo. The cases have been reported from two districts, Kampala and Wakiso, both part of the Kampala Metropolitan Area. To date, there has been no documented community transmission in Uganda. Exposure risks are associated with healthcare settings and cross-border movements. Following case reclassification, the number of affected healthcare workers was revised from five to four. In total 10 recoveries have been reported to date. Of the 826 contacts listed as of 18 June, a total of 122 contacts are under active follow up and 694 contacts have completed their 21-day follow-up period. Figure 4: Number of confirmed cases (n = 19), in Uganda by date of reporting as of 18 June 2026

Since the last Disease Outbreak News was published on 8 June 2026, the number of confirmed cases and deaths have increased rapidly in the Democratic Republic of the Congo. In total, 695 confirmed cases; 676 from the Democratic Republic of the Congo and 19 from Uganda; and 138 deaths including two from Uganda, have been reported from both countries, while at least 37 people have recovered from the disease. Figure 1. Distribution of confirmed cases of Bundibugyo virus disease in the Democratic Republic of the Congo, as of 10 June; and Uganda, as of 11 June Democratic Republic of the Congo Since 8 June, an additional 161 confirmed cases, including 45 confirmed deaths, have been reported from the Democratic Republic of the Congo. The increase is in part due to the scale up of testing and diagnostic capacities, enabling testing of the backlog of previously collected samples. As of 10 June 2026, a total of 676 confirmed cases including 136 deaths (CFR 20.1%) have been reported from the Democratic Republic of Congo. The reported CFR is likely an underestimation, as many deaths that occurred before the outbreak declaration remain under investigation. So far, 32 patients have recovered. Cases have been reported from 29 health zones (HZ) from Ituri (19/36 HZ), North Kivu (9/35 HZ) and South Kivu provinces (1/34 HZ) [1]. Sixteen confirmed cases have been reported among health and care workers to date. The outbreak remains concentrated in Ituri Province, which accounts for 93% (629) of the confirmed cases with a CFR of 17.3% (109/629). The highest number of confirmed cases in Ituri Province are reported from Bunia (185 cases), Rwampara (137 cases), Mongbwalu (132 cases), and Nyankunde (33 cases) health zones. While the epicentre remains Ituri, there has been significant geographic expansion of health zones with confirmed cases since 8 June, with confirmed cases in additional four health zone as of 10 June. Of the total confirmed cases, 94 are awaiting distribution by HZ. As of 10 June, 5768 contacts have been identified and are under follow-up across Ituri (4703), North Kivu (841), and South Kivu (224) provinces. Of these, 4141 contacts have been followed up, corresponding to follow-up rates of 71.4% in Ituri, 71% in North Kivu, and 83.5% in South Kivu. The outbreak is unfolding in a complex humanitarian and conflict-affected environment, characterized by highly mobile and often displaced populations. These dynamics, combined with increasing security-related incidents affecting health facilities, have posed additional operational challenges in affected provinces, such as constrained access for response teams, disrupted surveillance and response activities, and heightened risk of undetected transmission. These conditions underscore the need for response efforts to be led by local leaders and anchored in communities. Figure 2: Number of confirmed cases (n = 676) in the Democratic Republic of the Congo, by date of reporting as of 10 June 2026 NB: Newly reported confirmed cases/deaths may be part of the back log of samples and therefore not necessarily newly acquired infections. Uganda Since the last update dated 8 June, no additional confirmed cases or death have been reported from Uganda. As of 10 June 2026, a cumulative of 19 confirmed cases including two deaths in imported cases, and one probable case who has died, have been reported. Of the confirmed cases, 14 cases are imported and five are secondary transmission among contacts and health workers following cases imported from the Democratic Republic of the Congo. The cases have been reported from two districts, Kampala and Wakiso, both part of the Kampala Metropolitan Area. To date, there has been no documented community transmission in Uganda. Exposure risks are associated with healthcare settings and cross-border movements. Five recoveries have been reported to date. Of the 820 contacts listed as of 11 June, a total of 409 contacts are under active follow up and 394 contacts have completed their 21-day follow-up period. Figure 3: Number of confirmed cases (n = 19) in Uganda by date of reporting as of 11 June 2026

Since the last Disease Outbreak News was published on 29 May 2026, the number of confirmed cases and deaths have increased rapidly in the Democratic Republic of the Congo and Uganda. In total, 534 confirmed cases including 93 deaths (case fatality rate [CFR] 17.4%) have been reported from both countries, while at least 17 people have recovered from the disease. Figure 1. Distribution of confirmed cases of Bundibugyo virus disease in the Democratic Republic of the Congo and Uganda, as of 6 June 2026 Democratic Republic of the Congo Since 29 May, an additional 390 confirmed cases including 74 confirmed deaths have been reported from the Democratic Republic of the Congo. The increase is in part due to the scale up of testing and diagnostic capacities, enabling testing of the backlog of previously collected samples. As of 6 June 2026, a total of 515 confirmed cases including 91 deaths (CFR 17.7%) have been reported from the Democratic Republic of Congo. The reported CFR is likely an underestimation as many deaths that occurred before the outbreak declaration remain under investigation. So far, 12 patients have recovered. Cases have been reported from 25 health zones (HZ) from Ituri (17/36 HZ), North Kivu (7/35 HZ) and South Kivu Provinces (1/34 HZ)[1]. Sixteen confirmed cases have been reported among health and care workers to date. The outbreak remains concentrated in Ituri Province, which accounts for 94% (487) of confirmed cases. The CFR in Ituri is 15% (74/487); significantly lower than the CFR in North Kivu which is 64% (16/25). The highest confirmed case numbers in Ituri Province are reported from Bunia (142 cases), Rwampara (98 cases), Mongbwalu (92 cases), and Nyankunde (24 cases) HZ. As of 6 June, 5040 contacts had been identified and were under follow-up across Ituri (4118), North Kivu (699), and South Kivu (223) provinces. Of these, 2535 contacts were followed up in the last 24 hours, corresponding to follow-up rates of 43.2% in Ituri, 82.5% in North Kivu, and 80.3% in South Kivu.Increasing security-related incidents affecting health facilities have posed additional operational challenges in affected provinces. These conditions are constraining access for the response, disrupting surveillance and response activities, and increasing the risk of undetected transmission. Such incidents underline the challenges of the context and the importance of working closely with local leaders and communities. Figure 2: Number of confirmed cases (n = 515), including deaths, in the Democratic Republic of the Congo, by date of reporting and as of 6 June 2026 NB: Newly reported confirmed cases/deaths may be part of the back log of samples and therefore not necessarily newly acquired infections. Uganda Since the last update dated 29 May, an additional 10 confirmed cases and one death have been reported from Uganda. As of 6 June 2026, a total of 19 confirmed cases including two deaths in imported cases, and one probable case who has died, have been reported. Five recoveries have been reported. Of the total cases, 14 cases are imported and five are Ugandans. The cases were reported from two districts Kampala and Wakiso. To date, all cases in Uganda can be linked to travelers from the Democratic Republic of the Congo, or secondary infections linked to them; there has been no documented community transmission in Uganda. Exposure risks are associated with healthcare settings and cross-border movements. About 70% of the cases are Congolese nationals who came to Uganda to seek medical care. This includes a Congolese national who travelled from the Democratic Republic of the Congo, via Uganda, to the United Arab Emirates and then back to Uganda. WHO is working with public health authorities in the United Arab Emirates and Uganda to gather additional information to assess the risk of exposure and facilitate contact tracing through the National International Health Regulations (IHR) Focal Point mechanism. Based on the information available to date, there is no evidence that the case exhibited clearly recognized symptoms consistent with BVD during travel to or from the United Arab Emirates. Following notification of the case, UAE authorities rapidly implemented risk assessment, contact tracing activities, follow-up of identified contacts, public health investigations, enhanced preparedness measures at points of entry, and coordination with relevant national and international partners. Epidemiological investigations to date have not identified any secondary cases, local transmission, or evidence of onward spread in the UAE. The findings support the conclusion that the risk of the transmission associated with this event in the United Arab Emirates is low. As of 2 June, a total of 668 contacts linked to the cases have been identified and are under follow-up. These include close residential contacts and hospital contacts where the cases were hospitalized. Figure 3: Number of confirmed cases (n = 19), including deaths, in Uganda by date of reporting and as of 6 June 2026

Since the last Disease Outbreak News was published on 21 May 2026, the number of suspected and confirmed cases has increased rapidly in the Democratic Republic of the Congo. In total, 906 suspected cases, including 223 deaths among suspected cases have been reported from Democratic Republic of the Congo; and 134 confirmed cases (nine in Uganda), including 18 deaths (one in Uganda) (CFR 14%) have been reported from the two countries as of 29 May. Additionally, a medical doctor from the United States of America who was exposed as part of their work caring for patients in the Democratic Republic of the Congo tested positive on 17 May and was transported to Germany for treatment and care. Figure 1. Distribution of suspected and confirmed cases of Bundibugyo virus disease in Democratic Republic of the Congo and Uganda, as of 29 May 2026 Democratic Republic of the Congo Since the last update dated 21 May, an additional 42 confirmed cases including eight deaths and 160 suspected cases including 47 deaths have been reported from the Democratic Republic of the Congo. As of 27 May 2026, a total of 125 confirmed cases including 17 deaths (CFR 14%); and 906 suspected cases including 223 deaths have been reported from 13 health zones (HZ) in Ituri (7/36 HZ), North Kivu (5/35 HZ) and South Kivu Provinces (1/34 HZ) [1]. Sixteen confirmed cases have been reported among health and care workers to date. Epidemiological and laboratory investigations are ongoing to reclassify all suspected cases and deaths reported in the Democratic Republic of the Congo. The outbreak remains concentrated in Ituri Province, which accounts for 88% (110) of confirmed cases. The highest confirmed case numbers in Ituri Province are reported from Bunia (37 cases), Rwampara (33 cases), Mongbwalu (20 cases), and Nyankunde (10 cases) HZ. Of the 17 deaths among confirmed cases in the Democratic Republic of the Congo, 10 were male (nine were over 15 years old and one under 15) and seven were female (five over 15 years old and two under 15). A total of 774 samples have been collected as of 27 May. Of these, 648 samples (84%) have been analyzed, with 125 testing positive, representing a test positivity rate (TPR) of 19.2%. This is likely an underestimation of the actual positivity rate as over 100 samples are still awaiting testing and have been sent to Kinshasa for further analysis. As of 27 May, 2635 contacts have been listed in Ituri and North Kivu provinces. Security incidents against health facilities, and community resistance, have recently emerged as major operational challenges in Ituri Province, with three recent incidents reported in Mongbwalu and Rwampara HZ. These create additional risks for undetected transmission, disrupt outbreak response efforts, and reinforce the need to strengthen community protection and engagement activities Figure 2: Number of confirmed cases (n=125) and deaths (n=17) by date of reporting in the Democratic Republic of the Congo as of 27 May 2026 Source: Ministry of Health, Democratic Republic of the Congo NB: Newly reported confirmed cases/deaths may be part of the back log of samples waiting to be tested and therefore not necessarily newly acquired infections. Uganda Since the last update dated 21 May, an additional seven confirmed cases have been reported from Uganda. As of 29 May 2026, a total of nine confirmed cases including one death have been reported in Kampala (n=8) and Wakiso (n=1), Uganda. Recent cases include a Ugandan driver who transported the first reported case, a Congolese health worker with linkage to the index case, a Congolese woman who travelled to Uganda for medical care, and two Ugandan health workers linked to earlier confirmed case. As of 26 May, a total of 436 contacts linked to the cases have been identified and are under follow-up. These include close household contacts and hospital contacts where the cases were hospitalized. Exposure risks are associated with healthcare settings and cross-border movements. Figure 3: Number of confirmed cases (n=9) and deaths (n=1) by date of reporting in Uganda as of 29 May 2026 Source: Ministry of Health, Uganda

On 2 May 2026, WHO received notification from the IHR NFP of the United Kingdom of Great Britain and Northern Ireland (hereafter referred to as the United Kingdom) regarding a cluster of severe acute respiratory illness, including two deaths and one critically ill passenger, aboard the Netherlands-flagged cruise ship M/V Hondius. As of 27 May, a total of 13 cases (eleven confirmed and two probable cases), including three deaths (two confirmed and one probable), have been reported. Since the last Disease Outbreak News was published on 13 May, three additional confirmed cases have been reported among passengers or crew members, one each from Canada, the Netherlands, and Spain. The case in Canada developed symptoms during contact follow-up, whereas the cases in the Netherlands and Spain were identified through routine weekly testing of high-risk contacts during follow-up. The previously reported inconclusive case from the United States of America was subsequently determined to be negative following further laboratory testing and has been removed from the total count on 15 May. All confirmed cases are among people who travelled onboard the M/V Hondius. Figure 1. Epidemiological curve of Andes hantavirus cases (n = 13) reported to WHO as of 27 May 2026, 17:00. Based on currently available information, the working hypothesis is that the first case acquired the infection prior to boarding the cruise, through exposure on land. Investigations are ongoing to elucidate the potential circumstances of exposure and the source of the outbreak, in collaboration with authorities in Argentina and Chile, however, the time between the individual’s visit to Chile and the onset of symptoms exceeds the maximum incubation period. Therefore, based on the information currently available, exposure in Chile can be ruled out. Current evidence suggests subsequent human-to-human transmission onboard the ship. This is also supported by a preliminary analysis of the sequences, which show a near-identical sequence from different cases.[1] This outbreak is being managed through a coordinated international response. This includes comprehensive epidemiological investigations, case isolation and clinical management, medical evacuations, laboratory testing, and international contact tracing, as well as quarantine and monitoring measures. Recommendations are subject to change as new epidemiological and laboratory evidence becomes available, including findings from genetic sequencing. Follow-up and contact tracing for all contacts of hantavirus cases linked to the cruise ship is ongoing. This includes passengers who disembarked in Saint Helena, United Kingdom, on 24 April; Ascension, United Kingdom, on 27 April; Praia, Cabo Verde, on 6 May; and Tenerife, Spain, on 10 and 11 May, the remaining 25 crew members and the two healthcare workers from the Netherlands who disembarked in the Netherlands on 18 May and 23 May. Passengers who travelled on flights who may have had exposure to subsequently confirmed cases have been identified and contacted. High-risk contacts are being quarantined and monitored by local health authorities either in their respective countries or in the ship’s flag country, the Netherlands, or third countries (Table 1). As of 22 May 2026, more than 600 contacts, including 53% high-risk and 47% low-risk contacts, have been identified across 32 countries, territories and areas, and are either under close monitoring or self-monitoring in line with the updated guidance on management of contacts of Andes virus (ANDV) cases from the MV Hondius cruise ship published on 17 May. Table 1. Contacts being traced for the Andes hantavirus outbreak on a cruise ship reported to WHO as of 25 May 2026, 17:00.

On 15 May 2026, the Ministry of Public Health, Hygiene and Social Welfare of Democratic Republic of the Congo (DRC) officially declared the 17th Ebola disease outbreak following the laboratory confirmation of Bundibugyo virus disease (BVD) in eight samples. Concurrently, on 15 May 2026, the Ministry of Health of Uganda confirmed an outbreak of BVD following the identification of an imported case from DRC. On 17 May 2026, the WHO Director-General, after having consulted the States Parties where the event is known to be currently occurring, determined that the Ebola disease caused by Bundibugyo virus in DRC and Uganda constitutes a public health emergency of international concern (PHEIC), as defined in the provisions of International Health Regulation (IHR) Since the last Disease Outbreak News was published on 16 May 2026, the number of suspected and confirmed cases has increased rapidly in DRC, with geographical expansion into North Kivu and South Kivu. In total, 746 suspected cases, including 176 deaths among suspected cases have been reported from DRC as of 21 May 2026; and 85 confirmed cases (two in Uganda), including ten deaths (one in Uganda) (CFR 12%) have been reported from both countries. Figure 1. Distribution of suspected and confirmed cases of Bundibugyo virus disease in Democratic Republic of Congo and Uganda, as of 21 May 2026 Democratic Republic of the Congo As of 21 May 2026, a total of 83 confirmed cases including nine deaths (CFR 11%); and 746 suspected cases including 176 deaths have been reported from 15 health zones (HZ) in Ituri, North Kivu and South Kivu Provinces, DRC. Four health worker deaths have been reported to date. Epidemiological and laboratory investigations are ongoing to reclassify all suspected cases and deaths reported in DRC. The most affected HZ are Mongbwalu, Rwampara and Bunia, which all account for 96% of suspected cases and 79% of confirmed cases. As of 21 May, 1603 contacts have been listed in Ituri province and one contact became a suspected case. However, follow-up remains weak due to insecurity and movement restrictions. The follow-up rate as of 21 May is 21%. On 21 May, 84 new alerts were reported, and 77 alerts were investigated, all of which were validated. An American national, who was working in DRC as a surgeon, has also been identified as a confirmed case. Exposure is thought to have occurred during a medical procedure on 11 May. Onset of symptoms was reported on 16 May and laboratory confirmation was received on 20 May. The case is currently at a High-Level isolation unit in Berlin, Germany undergoing treatment. Figure 2 Risk mapping of Health Zones in DRC as of 21 May 2026 Response efforts continue to face a number of challenges, including: absence of standardized isolation and treatment facilities and weak screening and referral pathways; inconsistent implementation of safe and dignified burial measures further underscores the significant risk of healthcare-associated transmission; cross-border transmission risks remain elevated due to insecurity, humanitarian crises, high population mobility, urban/semi-urban transmission hotspots, and porous borders, requiring intensified surveillance and information sharing; deeply challenging situation for affected communities, with growing concerns over access to free and supportive healthcare services, the ability to ensure respectful and dignified burials, and the spread of misinformation and rumour; ongoing conflict in Ituri province restricting the movement of surveillance teams, the deployment of Rapid Response Teams, and the transporting of laboratory samples. It is currently thought that the event originated in the Mongbwalu HZ, DRC, a high-traffic mining area, with cases subsequently migrating to Rwampara and Bunia to seek medical care. Ituri province borders South Sudan and Uganda with Bunia HZ being less than 40km from Uganda. A full epidemiological investigation and trace back exercise is ongoing. Ituri’s role as a commercial and migratory hub and proximity to Uganda and South Sudan increases the risk of regional exportation and cross-border transmission. Uganda As of 20 May 2026, a total of two confirmed cases including one death have been reported in Kampala, Uganda. Both cases were imported from the DRC. The first case was admitted to a private hospital on 11 May and died on 14 May. The transfer of the body to DRC was completed the same day. The second case was confirmed on 16 May in Kampala, in an individual returning from DRC with no apparent links to the first case. The case is currently admitted in Uganda at the Mulago Isolation Treatment Unit. At the time of reporting, no local transmission has been identified in Uganda. As of 18 May, a total of 127 contacts, linked to both confirmed imported cases, have been identified and under follow-up. These include close household contacts and hospital contacts where the cases were hospitalized. Exposure risks are associated with healthcare settings and cross-border movements. Eighteen alerts were reported on 18 May and investigated. Four active cross-border exposure clusters identified in Ntoroko District are under investigation.

On 5 May 2026, WHO received an alert regarding an unknown illness with high mortality reported in Mongbwalu Health Zone, Ituri Province, including four health workers who died within four days. Following an in-depth investigation by the rapid response team in Mongbwalu and Rwampara health zones (HZ) on 13 May, the outbreak was subsequently confirmed as Bundibugyo virus disease (BVD) due to Bundibugyo virus (BDBV) (Orthoebolavirus bundibugyoense, species) on 15 May. On 15 May 2026, the Ministry of Public Health, Hygiene and Social Welfare officially declared the 17th Ebola Disease outbreak in the DRC, occurring in Rwampara, Mongwalu and Bunia HZ. The first currently known suspected case, a health worker, reported onset of symptoms including fever, hemorrhaging, vomiting and intense malaise on 24 April 2026. The case died at a medical centre in Bunia. As of 15 May, a total of 246 suspected cases and 80 deaths (four deaths among confirmed cases) have been reported from three HZ: Rwampara (six health areas affected), Mongbwalu (three health areas affected), and Bunia . Twenty four suspected cases are currently in isolation facilities across the three HZ. In addition, unusual clusters of community deaths with symptoms compatible with Bundibugyo virus disease (BVD) are being investigated across other HZ in Ituri and North Kivu. A further case reported on 16 May, an individual returning from Ituri to Kinshasa, has tested NEGATIVE for Bundibugyo virus on confirmatory testing by the Institut National de la Recherche Biomédicale (INRB) of DRC, and is therefore not considered a confirmed case. Most of the suspected cases are between 20 and 39 years old, with females accounting for over 60%, suggesting significant risks associated with household and caregiver transmission. Initial testing of 20 samples collected in Rwampara HZ and analysed at the Provincial Public Health Laboratory in Bunia using standard Ebola Xpert were negative for Ebola virus. Samples were sent to INRB for further analysis, of which eight samples analysed were confirmed as Orthoebolavirus by polymerase chain reaction (PCR) on 15 May. Genomic sequencing confirmed the virus species as Bundibugyo virus (BDBV). As of 15 May, 65 contacts have been listed, with 15 identified as high-risk. However, follow-up remains weak due to insecurity and movement restrictions. Several listed contacts became symptomatic and died before they could be isolated. On 15 May 2026, the Ministry of Health of Uganda confirmed an outbreak of BVD following the identification of an imported case from the DRC. The case is an elderly man who was admitted to a private hospital on 11 May with severe symptoms and died on 14 May. The post-mortem transfer of the body to DRC was completed the same day. A clinical sample collected when the case was admitted on 11 May was tested at the Central Emergency Surveillance and Response Support Laboratory, Wandegeya, and was confirmed as Bundibugyo virus on 15 May 2026. A second imported case was confirmed on 16 May in Kampala, in an individual returning from DRC with no apparent links to the first case. At the time of reporting, no local transmission has been identified in Uganda. On 17 May 2026, the Director-General of WHO, after having consulted the States Parties where the event is known to be currently occurring as defined in the provisions of the International Health Regulations (2005) (IHR), determined that the Ebola disease caused by Bundibugyo virus in DRC and Uganda constitutes a PHEIC. It is currently thought that the event originated in the Mongbwalu HZ, DRC, a high-traffic mining area, with cases subsequently migrating to Rwampara and Bunia to seek medical care. Ituri province borders South Sudan and Uganda (and Bunia HZ is less than 500km from Uganda). A full epidemiological investigation and trace back exercise is ongoing. Ituri’s role as a commercial and migratory hub and proximity to Uganda and South Sudan increases the risk of regional exportation and cross-border transmission. Figure 1. Health Zones affected by Bundibugyo virus disease in Democratic Republic of Congo, as of 16 May 2026

On 2 May 2026, WHO received notification from the IHR NFP of the United Kingdom of Great Britain and Northern Ireland (hereafter referred to as the United Kingdom) regarding a cluster of severe acute respiratory illness, including two deaths and one critically ill passenger, aboard the Dutch-flagged cruise ship MV Hondius. As of 13 May, a total of 11 cases (eight confirmed, one inconclusive and two probable cases), including three deaths (two confirmed and one probable), have been reported. Since the last Disease Outbreak News was published on 8 May, two additional confirmed cases and one inconclusive case have been reported among passengers. These are one confirmed case from France, who became symptomatic during repatriation, one confirmed case from Spain, tested upon arrival following repatriation but currently well and asymptomatic, and one case considered inconclusive. The latter was repatriated to the United States of America, is currently asymptomatic with inconclusive laboratory results (one positive and one negative result from two different laboratories), and is being retested. The individual was sampled due to high-risk exposure to confirmed cases on board. All laboratory-confirmed cases are confirmed for ANDV infection. All were passengers onboard the MV Hondius. Figure 1. Epidemiological curve of Andes hantavirus cases (n = 11) reported to WHO as of 13 May 2026, 17:00. Based on currently available information, the working hypothesis is that the first case acquired the infection prior to boarding the cruise, through exposure on land. Investigations are ongoing to elucidate the potential circumstances of exposure and the source of the outbreak, in collaboration with authorities in Argentina and Chile. Current evidence suggests subsequent human-to-human transmission onboard the ship. This is also supported by a preliminary analysis of the sequences, which show a close, near-identical sequenced from different cases.[1] The outbreak is being managed through a coordinated international response, including in-depth epidemiological investigations, case isolation and clinical management, medical evacuations, laboratory testing and international contact tracing, quarantining and monitoring. Recommendations may be updated as additional epidemiological and laboratory evidence, including genetic sequencing data, becomes available. Follow-up and contact tracing for all contacts of hantavirus cases linked to the cruise ship is ongoing. This includes passengers who disembarked in Saint Helena, United Kingdom, on 24 April; Praia, Cabo Verde, on 6 May; and Tenerife, Spain, on 10 and 11 May. Passengers who travelled on flights who may have had exposure to subsequently confirmed cases have been identified and contacted. Contacts are being monitored by local health authorities in their respective countries. On 10 May, the ship arrived in the Canary Islands, Spain, where disembarkation began. Passengers and most of the crew were repatriated from the Canary Islands to their respective residence countries or transit points via specially arranged non-commercial flights, with WHO and partners supporting the disembarkation process. The ship left the Canary Islands on 11 May and is sailing to the Netherlands, with 25 crew members remaining on board, along with two Dutch health and care workers to conduct their health monitoring and provide any healthcare that may be necessary.

On 2 May 2026, WHO received notification from the National IHR Focal Point of the United Kingdom of Great Britain and Northern Ireland (hereafter referred to as the United Kingdom) regarding a cluster of severe acute respiratory illness, including two deaths and one critically ill passenger, aboard a Dutch-flagged cruise ship. Since the last Disease Outbreak News was published on 4 May, three of the suspected cases were confirmed, and one additional confirmed case was reported. As of 8 May, a total of eight cases (six confirmed and two probable cases), including three deaths (two confirmed and one probable), case fatality ratio 38%, have been reported. All six laboratory-confirmed cases were identified as Andes virus through virus specific polymerase chain reaction (PCR) or sequencing. Two medical evacuation flights, from Cabo Verde, carrying two symptomatic confirmed patients and one previously suspected case landed in the Netherlands on 6 and 7 May. As of 8 May, four patients are currently hospitalised, one in intensive care in Johannesburg, South Africa, two in different hospitals in the Netherlands and the other in Zurich, Switzerland. The previously suspected case was transferred directly to Germany, where she was tested, and both PCR and serology tests were negative for Andes virus, she is therefore no longer considered to be a case. Contact tracing of passengers who disembarked in St Helena is ongoing; passengers have been contacted and advised to self-monitor for symptoms. Additionally, passengers who travelled on the same flight from St Helena to South Africa with one of the cases who was subsequently confirmed, have been contacted. On 6 May, the ship left Cabo Verde, heading to the Canary Islands, Spain where disembarkation is planned. Further investigations into the potential exposure of the first case and the source of the outbreak are ongoing in collaboration with authorities in Argentina and Chile. The outbreak is being managed through a coordinated international response, including in-depth epidemiological investigations, case isolation and clinical management, medical evacuations, laboratory testing and international contact tracing and monitoring. Summary of confirmed and probable cases: Case 1: An adult male who boarded the ship on 1 April, after more than three months of travel in Argentina, Chile, and Uruguay. Developed symptoms on 6 April and died onboard on 11 April. No microbiological tests were performed. He is considered a probable case. Case 2: An adult female, who was a close contact of case 1, who travelled and boarded the ship with him, went ashore at Saint Helena on 24 April with gastrointestinal symptoms. She subsequently deteriorated on a flight to Johannesburg, South Africa, on 25 April. She died on 26 April in a Johannesburg clinic. On 4 May, she was subsequently confirmed by PCR testing with hantavirus infection. Case 3: An adult male who developed symptoms on 24 April. He was disembarked and medically evacuated from Ascension Island on 27 April and is currently hospitalised in an Intensive Care Unit (ICU) in Johannesburg, South Africa. PCR testing confirmed hantavirus infection on 2 May, and Andes virus was confirmed through sequencing. Case 4: An adult female, with onset of symptoms (fever and general malaise) on 28 April, later presenting with pneumonia, died on 2 May. A post-mortem sample was collected and sent to the Netherlands with the evacuated patients, where it was confirmed to be Andes virus. Case 5: An adult male, working as the ship doctor, reported onset of symptoms on 30 April, including fever, fatigue, muscle pain, and mild respiratory symptoms. His samples confirmed PCR positivity for Andes virus on 6 May. The case was medically evacuated to the Netherlands on 6 May and is currently stable in isolation. Case 6: An adult male, working as a ship guide. Onset of symptoms was reported on 27 April with mild respiratory and gastrointestinal symptoms. Laboratory samples confirmed PCR positivity for Andes virus on 6 May. The case was medically evacuated to the Netherlands on 7 May and is currently stable in isolation. Case 7: An adult male, who disembarked in St Helena on 22 April and flew back to Switzerland on 27-28 April, through South Africa and Qatar. He started experiencing symptoms on 1 May after arrival in Switzerland, where he immediately self-isolated and reported to local public health authorities. He is currently hospitalised and in isolation in Switzerland. His samples confirmed PCR positivity for Andes virus on 5 May.[1] Case 8: An adult male, who disembarked in Tristan da Cunha on 14 April. Onset of symptoms was reported on 28 April with diarrhoea and two days later with fever. He is currently stable and in isolation. He is currently a probable case until laboratory confirmation. One case previously reported as suspected has now been reclassified as a non-case after testing negative for Andes virus through PCR and serology. Nevetheless, monitoring continues until the end of their incubation period from last exposure. Table 1. Distribution of reported Andes hantavirus cases by case status and outcome, as of 8 May 2026 Operational outbreak case definitions Suspected case: anyone who shared or visited a conveyance where there has been a confirmed or probable ANDV case AND with acute (or history of) symptoms compatible with ANDV infection, including fever (38°C or above), myalgia, chills, acute gastrointestinal (e.g. nausea, vomiting, diarrhoea, abdominal pain) or acute respiratory (e.g. cough, shortness of breath, chest pain, difficulty breathing) symptoms. Probable case: a person with signs and symptoms of a suspected case that has been evaluated by a health professional AND a known epidemiological link with a confirmed or probable ANDV case AND for which laboratory tests have not been conducted. Confirmed case: a person with laboratory confirmation of ANDV through RT-PCR or serology testing. Non-case*: a suspected or probable case who tests negative for ANDV by RT-PCR or serology. *Non-cases who develop symptoms compatible with the suspected case definition after a negative test and within the maximum incubation period after last exposure to a probable or confirmed case should be retested and reclassified as appropriate. Figure 1. Epidemiological curve of Andes hantavirus cases reported to WHO as of 8 May 2026, 17:00. Based on currently available information, the working hypothesis is that case 1 most probably acquired the infection prior to boarding through environmental exposure during activities he conducted in Argentina. Investigations are ongoing to assess the full itinerary of his activities and possible exposure factors. Current evidence points to subsequent human-to-human transmission onboard (Figure 1), given documented epidemiological links of some of the subsequent cases with case 1 during his illness, and the timing of their symptom onset, which clusters around the most likely incubation periods previously documented for ANDV. However, ongoing epidemiological and sequencing investigations will help better understand the epidemiological links between cases and their most likely exposure.

On 2 May 2026, WHO received notification from the National International Health Regulations (2005) (IHR) Focal Point of the United Kingdom of Great Britain and Northern Ireland (hereafter referred to as the United Kingdom) regarding a cluster of severe acute respiratory illness, including two deaths and one critically ill passenger, aboard a Dutch-flagged cruise ship. On 2 May 2026, laboratory testing conducted in South Africa confirmed hantavirus infection in one patient who is critically ill and in intensive care. On 3 May, one additional death was reported. A further three suspected cases remain on board. As of 4 May, a total of seven (two confirmed and five suspected) cases, including three deaths, have been reported. The vessel departed Ushuaia, Argentina, on 1 April 2026 and followed an itinerary across the South Atlantic, with multiple stops in remote and ecologically diverse regions, including mainland Antarctica, South Georgia, Nightingale Island, Tristan da Cunha, Saint Helena, and Ascension Island. The extent of passenger contact with local wildlife during the voyage, or prior to boarding in Ushuaia remains undetermined. The vessel carries a total of 147 individuals, including 88 passengers and 59 crew members. Onboard passengers and crew represent 23 nationalities. As of 4 May 2026, the vessel is moored off the coast of Cabo Verde. Summary of cases: Case 1: An adult male developed symptoms of fever, headache, and mild diarrhoea on 6 April 2026 while on board the ship. By 11 April, the case developed respiratory distress and died on board on the same day. No microbiological tests were performed. The body of the passenger was removed from the vessel to Saint Helena (a British Overseas Territory) on 24 April. Case 2: An adult female, who was a close contact of case 1, went ashore at Saint Helena on 24 April 2026 with gastrointestinal symptoms. She subsequently deteriorated during a flight to Johannesburg, South Africa, on 25 April. She later died upon arrival at the emergency department on 26 April. On 4 May, the case was subsequently confirmed by PCR with hantavirus infection. Contact tracing for passengers on the flight has been initiated. Cases 1 and 2, had travelled in South America, including Argentina, before they boarded the cruise ship on 1 April 2026. Case 3: An adult male presented to the ship's doctor on 24 April 2026 with febrile illness, shortness of breath and signs of pneumonia. On 26 April, his condition worsened. He was medically evacuated from Ascension to South Africa on 27 April, where he is currently hospitalised in an Intensive Care Unit (ICU). Laboratory testing on an extensive respiratory pathogen panel was negative; however, polymerase chain reaction (PCR) testing confirmed hantavirus infection on 2 May 2026. Serology, sequencing and metagenomics are ongoing. Case 4: An adult female, with presentation of pneumonia, died on 2 May 2026. The onset of symptoms was on 28 April, with fever and a general feeling of being unwell. Three suspected cases have reported high fever and/or gastrointestinal symptoms and remain on board. Medical teams in Cabo Verde are evaluating the patients and collecting additional specimens for testing.